Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Receivables (2016 - 2025)

Sanofi (SNY) has disclosed Receivables for 11 consecutive years, with $11.5 billion as the latest value for Q4 2025.

  • Quarterly Receivables rose 18.09% to $11.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 billion through Dec 2025, up 18.09% year-over-year, with the annual reading at $11.2 billion for FY2025, 13.16% up from the prior year.
  • Receivables hit $11.5 billion in Q4 2025 for Sanofi, up from $9.7 billion in the prior quarter.
  • In the past five years, Receivables ranged from a high of $11.5 billion in Q4 2025 to a low of $8.9 billion in Q4 2022.
  • Historically, Receivables has averaged $10.1 billion across 5 years, with a median of $9.7 billion in 2024.
  • Biggest five-year swings in Receivables: rose 19.04% in 2023 and later dropped 8.3% in 2024.
  • Year by year, Receivables stood at $9.6 billion in 2021, then decreased by 6.76% to $8.9 billion in 2022, then grew by 19.04% to $10.6 billion in 2023, then decreased by 8.3% to $9.7 billion in 2024, then grew by 18.09% to $11.5 billion in 2025.
  • Business Quant data shows Receivables for SNY at $11.5 billion in Q4 2025, $9.7 billion in Q4 2024, and $10.6 billion in Q4 2023.